{"id":"enzalutamide-capsule","safety":{"commonSideEffects":[{"rate":"34","effect":"Fatigue"},{"rate":"20","effect":"Hot flashes"},{"rate":"21","effect":"Diarrhea"},{"rate":"30","effect":"Musculoskeletal pain"},{"rate":"12","effect":"Headache"},{"rate":"10","effect":"Upper respiratory tract infection"},{"rate":"0.5","effect":"Seizures"}]},"_chembl":{"chemblId":"CHEMBL1082407","moleculeType":"Small molecule","molecularWeight":"464.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enzalutamide binds to the ligand-binding domain of the androgen receptor with high affinity, preventing androgen (testosterone and DHT) from activating the receptor. This blocks the translocation of the androgen receptor into the nucleus and its interaction with DNA, thereby inhibiting the expression of androgen-responsive genes essential for prostate cancer cell proliferation and survival. It is effective in both hormone-sensitive and castration-resistant prostate cancer.","oneSentence":"Enzalutamide is an androgen receptor inhibitor that blocks the binding and nuclear translocation of androgens, preventing androgen-driven gene transcription in prostate cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:59.629Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer"},{"name":"Non-metastatic castration-resistant prostate cancer"},{"name":"Metastatic hormone-sensitive prostate cancer"}]},"trialDetails":[{"nctId":"NCT04191096","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-12","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1251},{"nctId":"NCT04179864","phase":"PHASE1, PHASE2","title":"A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer","status":"TERMINATED","sponsor":"Epizyme, Inc.","startDate":"2019-11-18","conditions":"Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":102},{"nctId":"NCT05726292","phase":"PHASE2","title":"A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-01-06","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT07230106","phase":"PHASE2","title":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-08","conditions":"Prostate Cancer","enrollment":218},{"nctId":"NCT06855277","phase":"PHASE3","title":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-01","conditions":"Prostate Cancer","enrollment":940},{"nctId":"NCT06894511","phase":"PHASE2","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-09-11","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":7},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT04076059","phase":"PHASE3","title":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma China, Inc.","startDate":"2019-09-11","conditions":"Metastatic Hormone Sensitive Prostate Cancer","enrollment":180},{"nctId":"NCT04729114","phase":"PHASE1","title":"A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-06-14","conditions":"Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer","enrollment":174},{"nctId":"NCT07311694","phase":"PHASE3","title":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-02-02","conditions":"PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer","enrollment":370},{"nctId":"NCT07241416","phase":"PHASE3","title":"A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-05","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","enrollment":156},{"nctId":"NCT02003924","phase":"PHASE3","title":"Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10-31","conditions":"Nonmetastatic Castration-Resistant Prostate Cancer, Prostate Cancer, Cancer of the Prostate","enrollment":1401},{"nctId":"NCT04655365","phase":"PHASE2","title":"Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2022-03-22","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT05457257","phase":"PHASE4","title":"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":43},{"nctId":"NCT04446117","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2020-10-19","conditions":"Metastatic Prostate Cancer, Prostate Adenocarcinoma","enrollment":575},{"nctId":"NCT06126731","phase":"PHASE1, PHASE2","title":"Combination Study of Antibiotics With Enzalutamide (PROMIZE)","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2023-11-02","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":39},{"nctId":"NCT03734653","phase":"EARLY_PHASE1","title":"Testosterone Therapy in Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2019-01-18","conditions":"Prostate Cancer, Castration-Resistant Prostate Cancer","enrollment":30},{"nctId":"NCT04934722","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-05-25","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":186},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":"Prostate Cancer Metastatic","enrollment":3360},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT02007512","phase":"PHASE2","title":"Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-12-16","conditions":"Breast Cancer","enrollment":247},{"nctId":"NCT05413421","phase":"PHASE1","title":"Study of ORIC-944 in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"ORIC Pharmaceuticals","startDate":"2022-06-01","conditions":"Metastatic Prostate Cancer","enrollment":250},{"nctId":"NCT03568656","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 in Advanced Tumours","status":"COMPLETED","sponsor":"CellCentric Ltd.","startDate":"2018-07-23","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer","enrollment":220},{"nctId":"NCT03834493","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-07-28","conditions":"Prostatic Neoplasms","enrollment":1244},{"nctId":"NCT04363164","phase":"PHASE2","title":"Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-08-19","conditions":"Castration Resistant Metastatic Prostate Cancer","enrollment":150},{"nctId":"NCT02319837","phase":"PHASE3","title":"Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2014-12-17","conditions":"Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate","enrollment":1068},{"nctId":"NCT05650476","phase":"","title":"Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)","status":"AVAILABLE","sponsor":"Pfizer","startDate":"","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":""},{"nctId":"NCT03834519","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-02","conditions":"Prostatic Neoplasms","enrollment":793},{"nctId":"NCT04332744","phase":"PHASE2","title":"Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-09-02","conditions":"Metastatic Prostate Cancer","enrollment":54},{"nctId":"NCT06702995","phase":"PHASE1, PHASE2","title":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Evopoint Biosciences Inc.","startDate":"2023-04-19","conditions":"Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)","enrollment":307},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT03641560","phase":"PHASE4","title":"A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2018-09-19","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":52},{"nctId":"NCT02288247","phase":"PHASE3","title":"A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2014-12-01","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":688},{"nctId":"NCT02091960","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-09-05","conditions":"HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)","enrollment":103},{"nctId":"NCT03851640","phase":"PHASE3","title":"A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).","status":"RECRUITING","sponsor":"Hinova Pharmaceuticals Inc.","startDate":"2019-04-12","conditions":"MCRPC","enrollment":417},{"nctId":"NCT01889238","phase":"PHASE2","title":"Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-06-12","conditions":"Advanced, Androgen Receptor Positive Triple Negative Breast Cancer","enrollment":118},{"nctId":"NCT01650194","phase":"PHASE2","title":"A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-07-09","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":60},{"nctId":"NCT02918968","phase":"PHASE4","title":"Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-11-02","conditions":"Prostate Cancer","enrollment":206},{"nctId":"NCT02799745","phase":"PHASE2","title":"A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-06-09","conditions":"Prostate Cancer","enrollment":227},{"nctId":"NCT02116582","phase":"PHASE4","title":"A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-05-23","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":215},{"nctId":"NCT02528643","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-11-09","conditions":"Advanced Hepatocellular Carcinoma","enrollment":165},{"nctId":"NCT01977651","phase":"PHASE4","title":"A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2013-09-25","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC)","enrollment":424},{"nctId":"NCT01288911","phase":"PHASE2","title":"A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-03-22","conditions":"Prostatic Neoplasms","enrollment":375},{"nctId":"NCT02685397","phase":"PHASE2, PHASE3","title":"Management of Castration-Resistant Prostate Cancer with Oligometastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2016-10","conditions":"Castration-resistant Prostate Cancer Patients with Oligometastases","enrollment":102},{"nctId":"NCT06582628","phase":"PHASE2","title":"Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)","status":"RECRUITING","sponsor":"Fundacion Oncosur","startDate":"2024-07-05","conditions":"Metastatic Prostate Cancer","enrollment":78},{"nctId":"NCT02669771","phase":"","title":"Long-Term Specified Drug Use-Results Survey for Xtandi Capsule","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-11-30","conditions":"Castration-resistant Prostate Cancer","enrollment":1018},{"nctId":"NCT03177187","phase":"PHASE1, PHASE2","title":"Combination Study of AZD5069 and Enzalutamide.","status":"TERMINATED","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2017-11-13","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":30},{"nctId":"NCT03869762","phase":"PHASE2","title":"Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.","status":"TERMINATED","sponsor":"Cancer Trials Ireland","startDate":"2019-01-09","conditions":"Castration-resistant Prostate Cancer, Metastatic Cancer, Bone Metastases","enrollment":7},{"nctId":"NCT03016312","phase":"PHASE3","title":"A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-01-10","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":759},{"nctId":"NCT03685591","phase":"PHASE1","title":"PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-10-04","conditions":"Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell","enrollment":49},{"nctId":"NCT02453009","phase":"PHASE2","title":"Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Santa Chiara Hospital","startDate":"2014-10","conditions":"Prostatic Neoplasms","enrollment":246},{"nctId":"NCT04419402","phase":"PHASE2","title":"Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer","status":"UNKNOWN","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2020-08-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":162},{"nctId":"NCT04844749","phase":"PHASE3","title":"Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent","status":"TERMINATED","sponsor":"Veru Inc.","startDate":"2021-06-24","conditions":"Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer","enrollment":105},{"nctId":"NCT04033328","phase":"PHASE1","title":"Study of ORIC-101 in Combination With Enzalutamide","status":"TERMINATED","sponsor":"ORIC Pharmaceuticals","startDate":"2019-10-28","conditions":"Prostatic Neoplasms","enrollment":41},{"nctId":"NCT02987543","phase":"PHASE3","title":"Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-02-06","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":387},{"nctId":"NCT01995513","phase":"PHASE4","title":"Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10-22","conditions":"Prostate Cancer","enrollment":509},{"nctId":"NCT04628988","phase":"PHASE1","title":"A Study of CC-90011 and Comparators in Participants With Prostate Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2021-07-28","conditions":"Prostatic Neoplasms","enrollment":6},{"nctId":"NCT03569280","phase":"PHASE1","title":"Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients","status":"COMPLETED","sponsor":"Kangpu Biopharmaceuticals, Ltd.","startDate":"2019-11-26","conditions":"Castration-Resistant Prostate Cancer","enrollment":16},{"nctId":"NCT02740985","phase":"PHASE1","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-17","conditions":"Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","enrollment":313},{"nctId":"NCT03437941","phase":"PHASE1, PHASE2","title":"Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2017-12-15","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":39},{"nctId":"NCT02438007","phase":"PHASE3","title":"A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC","status":"TERMINATED","sponsor":"LTN PHARMACEUTICALS, INC.","startDate":"2015-06","conditions":"Prostate Cancer","enrollment":953},{"nctId":"NCT03464201","phase":"PHASE2","title":"Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study","status":"COMPLETED","sponsor":"Grupo Español de Tumores Huérfanos e Infrecuentes","startDate":"2018-04-13","conditions":"Ovarian Cancer","enrollment":16},{"nctId":"NCT04142060","phase":"PHASE2","title":"Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC","status":"TERMINATED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2020-06-01","conditions":"Breast Cancer","enrollment":34},{"nctId":"NCT01942837","phase":"PHASE2","title":"Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-09-13","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":67},{"nctId":"NCT02090114","phase":"PHASE2","title":"RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-08-25","conditions":"Prostate Cancer","enrollment":112},{"nctId":"NCT05422911","phase":"PHASE2","title":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2022-06-30","conditions":"Metastatic Cancer, Neoplasm, Prostate","enrollment":200},{"nctId":"NCT02485691","phase":"PHASE4","title":"Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-09","conditions":"Prostate Cancer Metastatic","enrollment":255},{"nctId":"NCT02588001","phase":"NA","title":"Japanese Research for Patients With Non-metastatic Castration Resistant Prostate Cancer - Enzalutamide","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2015-10-01","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT03753243","phase":"PHASE2","title":"Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"Mark Garzotto, MD","startDate":"2018-12-03","conditions":"Prostate Cancer","enrollment":32},{"nctId":"NCT02268175","phase":"PHASE2","title":"Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-10","conditions":"Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer","enrollment":75},{"nctId":"NCT04986176","phase":"PHASE3","title":"HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Applied Biology, Inc.","startDate":"2022-04-15","conditions":"COVID-19 Respiratory Infection","enrollment":602},{"nctId":"NCT02346578","phase":"PHASE2","title":"Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.","status":"COMPLETED","sponsor":"Taro Iguchi, MD, PHD","startDate":"2014-12","conditions":"Castration-resistant Prostate Cancer","enrollment":104},{"nctId":"NCT03478904","phase":"PHASE1","title":"Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-10","conditions":"Prostate Cancer","enrollment":1},{"nctId":"NCT02125084","phase":"PHASE1","title":"Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2014-10","conditions":"Prostate Cancer","enrollment":38},{"nctId":"NCT03103724","phase":"PHASE2","title":"A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.","status":"COMPLETED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2017-03-16","conditions":"Carcinoma Prostate","enrollment":68},{"nctId":"NCT02607228","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-12-08","conditions":"Metastatic Castrate-Resistant Prostate Cancer","enrollment":31},{"nctId":"NCT02286921","phase":"PHASE2","title":"Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-01","conditions":"Castration Resistant Metastatic Prostate Cancer","enrollment":222},{"nctId":"NCT03704519","phase":"PHASE1","title":"Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-10-23","conditions":"Cerebrovascular Circulation","enrollment":26},{"nctId":"NCT02215096","phase":"PHASE1","title":"Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-13","conditions":"Neoplasms","enrollment":37},{"nctId":"NCT02471469","phase":"","title":"Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-10","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":40},{"nctId":"NCT02384382","phase":"PHASE2","title":"A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-11-30","conditions":"Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer","enrollment":23},{"nctId":"NCT01212991","phase":"PHASE3","title":"A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09-16","conditions":"Prostate Cancer","enrollment":1717},{"nctId":"NCT02034552","phase":"PHASE2","title":"A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-07","conditions":"Prostatic Neoplasms","enrollment":68},{"nctId":"NCT01597193","phase":"PHASE1","title":"Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-04-30","conditions":"Breast Cancer","enrollment":101},{"nctId":"NCT01565928","phase":"PHASE1","title":"Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-01-24","conditions":"Prostate Cancer","enrollment":23},{"nctId":"NCT01927627","phase":"PHASE2","title":"Enzalutamide in Patients With High-risk Prostate Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2013-11-11","conditions":"Adenocarcinoma of the Prostate","enrollment":42},{"nctId":"NCT01091103","phase":"PHASE2","title":"Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-02-18","conditions":"Metastatic Progressive Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT02929576","phase":"PHASE3","title":"Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2016-09","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT02441517","phase":"PHASE4","title":"A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-10-28","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":4},{"nctId":"NCT01605227","phase":"PHASE3","title":"Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100","status":"COMPLETED","sponsor":"Exelixis","startDate":"2012-07","conditions":"Prostate Cancer, Castration Resistant Prostate Cancer, Pain","enrollment":1028},{"nctId":"NCT03196388","phase":"PHASE2","title":"Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate Cancer","status":"UNKNOWN","sponsor":"Fundación Canaria de Investigación Sanitaria","startDate":"2017-12-27","conditions":"Prostate Carcinoma","enrollment":70},{"nctId":"NCT02380313","phase":"PHASE1","title":"Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2015-10","conditions":"Cancer","enrollment":""},{"nctId":"NCT01902251","phase":"PHASE1","title":"Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-11","conditions":"Prostate Cancer, Pharmacokinetics of Enzalutamide","enrollment":27},{"nctId":"NCT01911741","phase":"PHASE1","title":"A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-11","conditions":"Healthy Subjects, Castration Resistant Prostate Cancer (CRPC), Relative Bioavailability","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xantdi","Xtandi","ASP-9785","MDV3100"],"phase":"phase_3","status":"active","brandName":"Enzalutamide capsule","genericName":"Enzalutamide capsule","companyName":"CHU de Quebec-Universite Laval","companyId":"chu-de-quebec-universite-laval","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enzalutamide is an androgen receptor inhibitor that blocks the binding and nuclear translocation of androgens, preventing androgen-driven gene transcription in prostate cancer cells. Used for Metastatic castration-resistant prostate cancer, Non-metastatic castration-resistant prostate cancer, Metastatic hormone-sensitive prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}